- Home
- / NKGen Biotech
NKGen Biotech
Stock Price
$0.3
2024-10-29
Market Capitalization
$11 M
2024-10-29
NKGen Biotech Summary
Company Summary
- Overview
- NKGen Biotech (formerly known as NKMax America) is a biotechnology company that develops cell therapies for neurodegenerative and oncological diseases based on activated NK cells.
- Type
- Public
- Status
- Active
- Founded
- 2017
- HQ
- Santa Ana, CA, US | view all locations
- Website
- https://nkgenbiotech.com/
- Cybersecurity rating
Table of Contents
Key People
Yongman Kim, Chief Scientific Officer
James Graf, Interim CFO
Paul Chang, VP, Development Operations
LocationsView all
1 location detected
Santa Ana, CA HQ
United States
3001 Daimler St
NKGen Biotech Financials
Summary Financials
- Net income (Q1, 2025)
- $15.4M
- Cash (Q1, 2025)
- $6.0K
- EBIT (Q1, 2025)
- ($4.7M)
- Enterprise value
- $27.0M